In order for HIV to replicate, the viral genome must enter into the cell nucleus and integrate into the host cell chromosome. Previous work suggests that the entry proceeds through nuclear pore ...
Caption: Structure of a HIV capsid (Left) Central slice view of a HIV virus-like particle with pore-forming toxin on the membrane (Middle) Atomic model of a HIV capsid (Right) Density map of HIV ...
Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (p24) subunits in hexamers. Surface plasmon resonance sensorgrams ...
– Phase 1b Study Demonstrates Potent Antiviral Efficacy Following a Single Subcutaneous Injection of GS-6207, No Discontinuations Due to Adverse Events – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
-Oral Presentation at ESGCT Highlights Potential of JCR’s Proprietary JUST-AAV Platform to Facilitate More Efficient Delivery While Reducing Liver Tropism- HYOGO, Japan, October 07, 2025--(BUSINESS ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback